Osiris Therapeutics, Inc., a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company’s products include Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and Crohn’s disease; in phase II clinical trials for the treatment of Type I diabetes and acute myocardial infarction; in preclinical stage for the treatment of acute radiation syndrome; and Chondrogen, a phase I/II clinical trial used for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with JCR Pharmaceuticals Co., Ltd.; Genzyme Corporation; Juvenile Diabetes Research Foundation; and Blackstone Medical, Inc. The company was founded in 1992 and is headquartered in Columbia, Maryland.
Osiris was re-introduced to me by the tireless man who runs the InvestorsLive.com blog this past weekend. The good folks in #smallcaps were privy to this intraday chart early on Tuesday:
[09:40] <digs> OSIR 15min http://img153.imageshack.us/my.php?image=screenshot091ov6.png